TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells.
Two products from the adipose-derived stem cell technology platform are currently in clinical development.
- Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients.
On July 4, 2016, we entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States.
- Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis.
Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI).
In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication.
TiGenix is based in Leuven, Belgium, and has operations in Madrid, Spain.
Show more| Type | Subsidiary |
| Parent Company | Takeda Pharmaceutical |
| HQ | Leuven, BE |
| Founded | 2000 |
| Website | tigenix.com |
| Cybersecurity rating | AMore |
TiGenix was founded in 2000 and is headquartered in Leuven, BE
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at TiGenix
Claudia DAugusta
Chief Financial Officer and General Manager
Wilfried Dalemans
CTO
Marie Paule Richard
Chief Medical Officer
Maria Pascual
Vice President, Regulatory Affairs and Corporate Quality
Mary Carmen Diez
Vice President, Medical Affairs and Commercialisation
Susana Rojo
Director of Human Resources
TiGenix Office Locations
TiGenix has an office in Leuven
Leuven, BE (HQ)
12 Romeinse straat
TiGenix Financials and Metrics
Summary Metrics
Founding Date | 2000 |
Total Funding | $37.5 m |
Investors | Kreos Capital |
TiGenix is a subsidiary of Takeda Pharmaceutical
TiGenix Cybersecurity Score
TiGenix Online and Social Media Presence
TiGenix's Trends
TiGenix News and Updates
June 19, 2018
Anal Fistula Treatment Market to Gain US$ 800 Mn in 2026, Says TMR
ALBANY, New York, June 19, 2018 /PRNewswire/ --
Transparency Market Research (TMR) has published a new report titled, "Anal Fistula Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018-2026". According to the report, the global anal fistula...
March 01, 2018
Takeda to add plant, 70 jobs in Ireland as it builds on deal for TiGenex
Takeda, which recently announced a $627 million deal to buy biotech TiGenix, is upping its bet on its stem cell therapy investment, with a new plant and 70 jobs at its manufacturing site in Ireland.
January 09, 2018
Bone Grafts And Substitutes Market Expand Their Businesses With New Investments by 2025
Bone grafts and substitutes (BGS) comprise the products that are used for the replacement of missing bones or to repair bone fractures. Posted via Industry Today. Follow us on Twitter @IndustryToday
TiGenix Blogs
July 31, 2018
Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period (EN – NL – FR – ES)
Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period (EN – NL – FR – ES)
July 06, 2018
Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix and Commencement of Simplified Squeeze-out and Intention to Delist the ADSs from Nasdaq, Terminate the ADS Facility and Terminate TiGenix’s U.S. Reporting Obligations (EN – NL – FR – ES)
Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix and Commencement of Simplified Squeeze-out and Intention to Delist the ADSs from Nasdaq, Terminate the ADS Facility and Terminate TiGenix’s U.S. Reporting Oblig…
June 22, 2018
Transparency notification pursuant to Article 14 of the Law of May 2, 2007
Transparency notification pursuant to Article 14 of the Law of May 2, 2007 (EN – NL)
June 19, 2018
Transparency notifications pursuant to Article 14 of the Law of May 2, 2007
Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (EN – NL)
June 14, 2018
Transparency notification pursuant to Article 14 of the Law of May 2, 2007 ( EN – NL )
Transparency notification pursuant to Article 14 of the Law of May 2, 2007 ( EN – NL )
TiGenix Frequently Asked Questions
When was TiGenix founded?
TiGenix was founded in 2000.
Who are TiGenix key executives?
TiGenix's key executives are Claudia DAugusta, Wilfried Dalemans and Marie Paule Richard.
How many employees does TiGenix have?
TiGenix has 57 employees.
Who are TiGenix competitors?
Competitors of TiGenix include Kither Biotech, CANbridge Life Sciences and Zytoprotec.
Where is TiGenix headquarters?
TiGenix headquarters is located at 12 Romeinse straat, Leuven.
Where are TiGenix offices?
TiGenix has an office in Leuven.
How many offices does TiGenix have?
TiGenix has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies